Company / SG&A Expense
Allogene Therapeutics, Inc. SG&A Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$56.8M
FY2025
5-year range
$39.4M / $74.1M
FY2021-FY2025
Trend
-20.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $74M to $57M over the past 2 years.
Based on SEC 10-K filings.
$57M in FY2025 with a 3-year CAGR of +12.9%.
Improved from $74M to $57M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +12.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +12.9%, indicating consistent growth.
- In FY2025, sg&a expense decreased 20.8% year-over-year.
- Peak sg&a expense was recorded in FY2023.
- Lowest sg&a expense in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $56.8M | -20.8% |
| FY2024 | $71.7M | -3.3% |
| FY2023 | $74.1M | +88.1% |
| FY2022 | $39.4M | -31.4% |
| FY2021 | $57.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026